C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
Returns on capital
C4 Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.9%
avg -22.9%
ROIC
-31.4%
avg -29.2%
ROA
-29.2%
avg -24.6%
Analysis
ROA is currently the strongest return metric at -29.2% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Andrew J. Hirsch | Chief Executive Officer, President & Director | USD 1.38M | 55 | — | — |
Leonard J. Reyno | Chief Medical Officer | USD 1.03M | 64 | — | — |
Kendra Adams | Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | USD 869.51K | 49 | 337.15K | 0.41% |
Kenneth C. Anderson | Co-Founder, Independent Director & Member of Scientific Advisory Board | USD 45.75K | 75 | — | — |
Christopher Nasveschuk | Senior Vice President of Chemistry | — | — | — | — |
Isabel Chiu | Senior Vice President of Strategic Alliances & Business Development | — | — | — | — |
Nathanael S. Gray | Co-Founder & Member of Scientific Advisory Board | — | — | — | — |
Roy Pollock | Senior Vice President of Biological Sciences | — | — | — | — |
Courtney Solberg | Senior Manager of Investor Relations | — | — | — | — |
Kelly Schick | Chief People Officer | — | 46 | 299.88K | 0.36% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$144,686.59
Net Transaction Value
−$144,686.59
Net selling
Most Active
Adams Kendra
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 12, 26Nov 12, 2026 | Adams Kendra Direct | Sell | $122.5K$122,486.59 |
| Jan 16, 26Jan 16, 2026 | REYNO LEONARD Direct | Sell | $22.2K$22,200.00 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $144,686.59 over the last 12 months. That adds up to net selling of $144,686.59. Adams Kendra was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +5.0% | +135.8% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.0% over three years. Forward estimates point to Revenue at +135.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does C4 Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CCCC's management, answered from reported figures.
Who manages CCCC?
C4 Therapeutics, Inc. (CCCC) lists 10 active executives. The top listed executive is Christopher Nasveschuk, Senior Vice President of Chemistry.
Are CCCC insiders buying or selling?
Recent insider activity shows net buying of $9.08M.
Continue the stock analysis
Jump to another research area for this company.